Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
60 participants
INTERVENTIONAL
2023-01-31
2025-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nicergoline low dose
Nicergoline 10 mg bid (20 mg/day)
Nicergoline
The participants in both arms will receive nicergoline for treatment dysphagia 12 weeks.
Nicergoline high dose
Nicergoline 30 mg bid (60 mg/day)
Nicergoline
The participants in both arms will receive nicergoline for treatment dysphagia 12 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nicergoline
The participants in both arms will receive nicergoline for treatment dysphagia 12 weeks.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Stroke (post events at least 2 months), Parkinson's disease and dementia patients who have dysphagia symptom
* Do not take nicergoline prior recruit 2 weeks
* Continue current medications
* Consent to join
Exclusion Criteria
* On anticoagulants including Heparin, Enoxaparin, Fondaparinux, Warfarin, Dabigatran, Apixaban, Rivaroxaban and Edoxaban
* On antiplatelet \> 1 drug (ex. dual antiplatelet)
* On ACE-I or Dopaminergic agent 2 months or less
* Chronic dyspepsia
* Chronic gout or hyperuricemia \> 8 mg/dL
* CrCl \< 30 ml/min
* Impair hepatic function including child puge B, C or active hepatitis
* Brainstem stroke
* Parkinson plus syndrome: PSP, MSA, DLB, etc
* Advanced cancer or other medical conditions
* Bed ridden
* Laryngopharynx surgery
* SBP\<100 or DBP 60 mmHg
* HR\<50/min
* Active bleeding
* Pregnancy or lactation
* Known of poor compliance for any treatments
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Silpakorn University
OTHER
Phramongkutklao College of Medicine and Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jutikan Imsub, PharmD
Role: STUDY_CHAIR
College of Pharmacy, Burapha university
Sittichoke Sirimontakan, MD
Role: PRINCIPAL_INVESTIGATOR
Phramongkutklao hospital and College of Medicine
Juthathip Suphanklang, BCP
Role: STUDY_DIRECTOR
Phramongkutklao hospital and College of Medicine
Pasiri Sithinamsuwan, MD
Role: STUDY_DIRECTOR
Phramongkutklao hospital and College of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Phramongkutklao Hospital
Ratchathewi, Bangkok, Thailand
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jutikan Imsub, PharmD
Role: primary
Pasiri Sithinamsuwan, MD
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIDY-2022
Identifier Type: -
Identifier Source: org_study_id